After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The drug titan reports Tuesday. Will a Dec. 24 cancer drug approval be an early Christmas gift?
Vale may be worth following again. Bristol-Myers? Not so much.
Cramer says P&G is a good choice and is disappointed by Bristol-Myers Squibb.
A malaise has once again befallen America, Cramer says.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.